[The new face of tuberculosis in the context of the tuberculosis-HIV association in Abidjan, Ivory Coast].
This article reviews the main clinical aspects and progression of HIV-related tuberculosis in Abidjan. HIV prevalence in tuberculosis patients is high, estimated at 46.2% in 1992, with a clear predominance of HIV-1 over HIV-2. More than 61% of co-infected tuberculous patients meet the WHO's clinical definition of AIDS (the Bangui definition) at the time of diagnosis of tuberculosis. This rates falls to 46-51% when cough is excluded from the definition. On X-rays, the signs of pulmonary tuberculosis in co-infected tuberculous patients are atypical in the advanced stages of HIV infection, when extra-pulmonary localization, mainly mediastinal adenopathy, is frequent. Short-course chemotherapy consisting of 2 months' unsupervised daily treatment with rifampicin/isoniazid/pyrazinamide, followed by 4 months of a daily combination of rifampicin/isoniazid, applied in the Ivory Coast since 15 July 1985, has proved successful in HIV-associated tuberculosis, with treatment effectiveness rates of more than 90%.
Domoua
K
K
Service de pneumophtisiologie, CHU de Treichville, Abidjan, Côte d'Ivoire.
Coulibaly
G
G
N'Dhatz
M
M
Traore
F
F
Kanga
K
K
Konan
J B
JB
Beugre
L K
LK
Yapi
A
A
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002648:Child; D007560:Cote d'Ivoire / Q000453:epidemiology; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications*; D015528:HIV Seroprevalence; D015497:HIV-1; D015498:HIV-2; D006801:Humans; D011859:Radiography; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000000981:diagnostic imaging
D000995:Antitubercular Agents